Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles & Cell-Free RNAs 2023

Extracellular Vesicles & Cell-Free RNAs 2023 Agenda

Co-Located Conference Agendas

Extracellular Vesicles & Cell-Free RNAs 2023 | Lab-on-a-Chip & Microfluidics World Congress 2023 | Materials & Tools for Developing POC & Rapid Dx 2023 | 

Print Agenda

Tuesday, 28 November 2023

Please View Programming Details of November 28, 2023 on Lab-on-a-Chip Agenda

Wednesday, 29 November 2023


Conference Registration and Materials Pick-Up + Coffee-Pastries in the Exhibit Hall

Welcome and Introduction by Conference Co-Chairs: Professor Morgan and Professor Graner

Session Title: State of the Extracellular Vesicles Field, circa 2023


Shannon StottKeynote Presentation

Immune-Associated Extracellular Vesicles in Blood
Shannon Stott, Assistant Professor, Massachusetts General Hospital & Harvard Medical School, United States of America


Leyla EsfandiariKeynote Presentation

Electrokinetic-based Microchip for Purification and Characterization of Small Extracellular Vesicles
Leyla Esfandiari, Associate Professor of Biomedical Engineering, University of Cincinnati, United States of America

Small extracellular vesicles (sEVs) are lipid-bilayer delimited particles that are naturally secreted by all cells and have emerged as valuable biomarkers for a wide range of diseases. Efficient isolation of sEVs while maintaining yield and purity is crucial to harvest their potential in diagnostic, prognostic, and therapeutic applications. However, because of the complex nature of samples and the heterogeneous physicochemical properties of EVs, their accurate isolation and characterization from body fluids raises significant challenges in clinical settings. We have developed and patented a simple, yet powerful electrokinetic-based microchip capable of rapid and label-free purification of sEVs from body fluids by applying a significantly low electric field. The device also tailored with a sensing module to further characterize sEVs based on their dielectric properties by measuring their impedance. Thus, the microchip has significant potential to serve as a bioanalytical tool for liquid biopsy.


Jennifer JonesKeynote Presentation

Extracellular Biology and Liquid Biopsies: What is Next?
Jennifer Jones, NIH Stadtman Investigator, Head of Transnational Nanobiology, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, United States of America


Mid-Morning Coffee Break and Networking in the Exhibit Hall


Brian EliceiriKeynote Presentation

Mechanisms of Extracellular Vesicle Biogenesis that Regulate Wound Healing
Brian Eliceiri, Professor, UC San Diego, United States of America

Small extracellular vesicles (EVs) are important mediators of intercellular signaling that carry biologically active protein payloads relevant in wound healing.  However, whether EVs are analyzed from wound fluid or other biological fluids, EVs are heterogenous, reflecting in part the release of EVs from different cell types.  To address the central question of EV heterogeneity in parallel with the unmet need for in vivo sources of EVs with low platelet contamination, we have developed a macroporous scaffold for the subcutaneous implantation and subsequent collection of EVs that is applicable for the study of EV activity in any defined mouse model. Using polyvinylalcohol (PVA) sponges as the scaffold, we first show that the rapid infiltration of immune cells of hematopoietic origin is accompanied a substantial and heterogenous population of EVs. Second, we show how single vesicle flow cytometry (vFC) addresses the heterogeneity challenge by quantifying the expression of surface markers that map to specific subpopulations of EVs relevant to cellular origin.  Third, we show how in vitro two-dimensional cell culture, although common, introduces significant bias in EV release that is addressed with the PVA scaffold in vivo model. Together these studies, define a novel model establishing the biochemical basis and biological activity of EVs in the biology of wound healing.


Larry ChamleyKeynote Presentation

Placental Extracellular Vesicles; Regulators of Maternal Physiology
Larry Chamley, Professor and Head of Department of Obstetrics and Gynaecology, University of Auckland, New Zealand

The human placenta produces vast quantities of extracellular vesicles into the maternal blood continuously during pregnancy. Biodistribution studies indicate that the majority of these EVs are taken up from the maternal blood rapidly in the lungs, liver kidneys and spleen. Functional studies demonstrate that normotensive placental EVs can protect against the development of hypertension long-term while EVs from pregnancies complicated by preeclampsia a hypertensive disease of pregnancy activate the maternal endothelium and induce a pro-constrictive phenotype in resistance arteries.  These functional studies suggest that the protein and/or regulatory RNA cargos of placental EVs have a long-lasting regulatory effect on  the maternal cardiovascular system.


Terry MorganConference Chair

Everything We Think We Know About Extracellular Vesicle Cargo is Wrong
Terry Morgan, Professor, Oregon Health and Science University, United States of America

Extracellular vesicles (EVs) comprise a range of submicron particles, including small EVs (exosomes ~75-150 nm) derived from endosomal biogenesis, larger microvesicles (< 1um) that bud directly from the cell membrane, and fragments of cells undergoing necrosis and/or apoptosis. These lipid encapsulated EVs contain surface cell-specific protein markers and a variety of RNAs that provide insights into their source and potential function (e.g. regulating angiogenesis and immune microenvironments).  Methods like density gradient ultracentrifugation followed by size-exclusion chromatography (SEC) provide a heterogeneous mixture of EVs from a variety of cell sources, and in a variety of sizes. Affinity capture lacks size-specificity, which is important because larger microvesicles are thought to have entirely different contents and biological functions than small EVs (exosomes). These methodological shortcomings have limited adequate EV profiling and characterization.  To address this need, the Morgan laboratory uses multiplex nanoscale fluorescent activated cytometric sorting (nanoFACS) with 40nm resolution to image, count, and isolate cell- and size-specific EVs. Importantly, this next generation approach provides highly efficient flow sorting of multiplex-labeled EVs at the 0.3 nanoliter droplet scale (5x better than commercially available FACS machines using our custom made sorting nozzle and EV-specific protocol).  We have completed validation studies characterizing flow sorted placental EVs according to guidelines put forth by the International Society of Extracellular Vesicles (ISEV), including nanoparticle tracking analysis, CryoEM, ELISA, and microRNA content within small EVs compared with flow sorted 100nm liposomes spiked into the same plasma samples. Spiked in liposomes are an important negative control for background contamination inherent in any EV isolation method and novel to our EV isolation approach.


Networking Luncheon in the Exhibit Hall -- Network with Exhibitors, View Posters and Engage with Colleagues

Session Title: Technologies Driving the Extracellular Vesicles Field Forward, circa 2023


Daniel ChiuKeynote Presentation

Digital Flow Cytometry for the High-Throughput Multiplexed Analysis of Single Extracellular Vesicles and Particles
Daniel Chiu, A. Bruce Montgomery Professor of Chemistry, University of Washington, United States of America

Extracellular vesicles and particles (EVPs) play a central role in liquid biopsy, intercellular communication, and disease transmission and progression, and are emerging therapeutic tools. To better understand the biology of EVPs and fully unlock their diagnostic and therapeutic potential, it is critical to access quantitative information regarding their concentration, size, and biological heterogeneities. To meet this need, we have developed a single-molecule sensitive flow platform, which uses a high-throughput 12-channel flow analyzer that detects each and every fluorescent molecule flowing through a microfluidic channel, and enables multiparameter characterization of EVPs, including single-EVP phenotyping, sizing, and the absolute quantitation of EVP concentrations and biomarker copy numbers.  This new flow technology should have a broad range of applications, from analysis of single EVPs such as exosomes or RNA-binding proteins to characterization of therapeutic lipid nanoparticles, viruses, and proteins; it also provides absolute quantitation of non-EVP samples such as dyes, beads, and Ab-dye conjugates.


Particle Metrix GmbH and CEO, Particle Metrix Inc., USAParticle Metrix GmbH Technolology Spotlight Presentation
Sven Rudolf Kreutel, Chief Executive Officer, Particle Metrix GmbH and CEO, Particle Metrix Inc., USA


NanoFCMCombining Flow Cytometry and Particle Analysis to Meet the Challenges of EV Characterization
Michael Jacobs, Applications Scientist, NanoFCM

NanoFCM aims to bring reliable and quantitative measurements to the nanoscale to support the emergence of new classes of diagnostics and therapeutics. This presentation will focus on illustrating how our NanoAnalyzer platform is able to interrogate EVs one by one, utilizing high resolution side scatter detection and fluorescence to identify molecules of interest associated with individual particles and sub-populations. Various examples will be presented which demonstrate how this technology can be applied for gathering physical and phenotypic information of EVs.


Mid-Afternoon Coffee Break and Networking in the Exhibit Hall


Steve SoperKeynote Presentation

Screening Tests using Micro- and Nanofluidics for Early Detection of Ovarian Cancer with Extracellular Vesicles Serving as the Input
Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas, United States of America

We are developing screening tests consisting of novel hardware, biomarkers, and assays to service a number of diseases, including the early detection of cancer and viral infections. The commonality in these tests is that they consist of microfluidic devices made from plastics via injection molding. Thus, our tests can be mass produced at low-cost to facilitate bench-to-bedside transition and point-of-care testing (PoCT) for large scale population screening. The assays are based on the use of liquid biopsy markers as the input, which can be secured in a non- to minimally-invasive manner appropriate for screening. Recently we have focused on developing plastic nanofluidic devices, which provides unique opportunities for single-entity analyses – these devices can also be injection molded. In this presentation, we will discuss the evolution of our fabrication efforts of plastic-based microfluidic and nanofluidic devices as well as their surface modification to make devices appropriate for screening using extracellular vesicles (EVs) as the input. Then, we will discuss the application of the device and the associated assay for selection of rare liquid biopsy targets (EVs) from clinical samples to serve as screening tests. The specific application we will discuss is the analysis of EVs for the early detection of ovarian cancer. Ovarian cancer is the 5th most deadly cancer for women in the US and has a 46.2% 5-y survival rate. Unfortunately, ~85% of cases are diagnosed at a late stage of disease providing pore outcomes for these patients. Therefore, new strategies for early detection are required. The screening test we are developing consists of a microfluidic chip for EV affinity selection, which consists of a high density array of pillars surface-decorated with antibodies to efficiently select EVs followed by the label-free enumeration to determine elevated levels of EVs in the plasma of patients suspected of having ovarian cancer. Unique EV-associated surface proteins were discovered for selection of ovarian cancer EV specifically for the early detection of disease. The selected EVs were counted using a nano-Coulter Counter chip (nCC), which consisted of in-plane nanopores. Both steps of the screening test described here were carried out using a microfluidic and nanofluidic chips integrated to a control board for automating sample processing with results produced within 20 min.


SpectradyneAccurate Nanoparticle Size, Concentration, and Payload with Spectradyne’s ARC Particle Analyzer
Jean-Luc Fraikin, CEO, Spectradyne

Spectradyne’s ARC particle analyzer uses a unique combination of electrical and optical measurement techniques to accurately measure the size, concentration, and internal and external payload of nanoparticles as small as 50 nm in diameter.  Learn how scientists are using the ARC to quantify single-particle encapsulation efficiency for LNPs and characterize subpopulations of extracellular vesicles based on surface marker expression profiles.


Cytek BioSciencesCytek BioSciences Technology Spotlight Presentation
Stephanie Brunelle, Senior Product Manager, Cytek BioSciences


The University of KansasLiquid Biopsy Core (LBC) - Enabling Tools for the Isolation of Liquid Biopsy Markers and Their Molecular Analysis
Malgorzata Witek, Associate Research Professor, The University of Kansas

Liquid biopsies are minimally invasive tests that can be performed frequently, providing “real-time” information on disease status to improve patient outcome. Analyzing different biomarkers present in liquid biopsies, including circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs), requires enrichment to select the low abundant disease-associated markers from clinical samples. The LBC provides a diverse range of technologies that are directed at both enriching liquid biopsy markers and their downstream molecular analysis. The LBC uses a combination of microfluidics with full process automation for enriching the full complement of liquid biopsy markers with exquisite analytical figures-of-merit. As examples of utility of LBC technologies, we will present clinical data on identifying the molecular subtypes of breast cancer using EV’s mRNA and monitoring response to therapy in pancreatic cancer via CTCs.


Networking Reception with Beer and Wine in the Exhibit Hall


Close of Conference Day

Thursday, 30 November 2023


Morning Coffee, Pastries and Networking in the Exhibit Hall


Michael GranerConference Chair

Current Status of the EV Field -- Major Themes Emerging
Michael Graner, Professor, Dept of Neurosurgery, University of Colorado Anschutz School of Medicine, United States of America


CD47 Functions in Extracellular Vesicle RNA Cargo Loading and Extracellular Signaling in Cancer and Immune Cells
Sukhbir Kaur, Staff Scientist, National Cancer Institute, National Institutes of Health, United States of America


Beckman Coulter Technology Spotlight Presentation


BD Biosciences Technology Spotlight Presentation


Kendall Van Keuren-JensenKeynote Presentation

Extracellular RNAs Associated with Neurodegenerative Disease and Injury
Kendall Van Keuren-Jensen, Professor and Deputy Director, Translational Genomics Research Institute, United States of America


Mid-Morning Coffee Break and Networking in the Exhibit Hall

Add to Calendar ▼2023-11-28 00:00:002023-11-30 00:00:00Europe/LondonExtracellular Vesicles and Cell-Free RNAs 2023Extracellular Vesicles and Cell-Free RNAs 2023 in Laguna Hills, CaliforniaLaguna Hills,